Posted inDaily Brief

Suzano Set for FO

Suzano Papel e Celulose is set to raise more than BRL1.4bn ($680m) from a follow-on equity sale, scheduled to price this evening. The Brazilian pulp and paper producer is offering 99.7m common shares and 192.3m preferred shares, up from the 80m common and 164.9 preferred shares initially announced. This would indicate a BRL1.48bn size, based on Tuesday’s BRL4.40 preferred share closing price, if a 15% greenshoe is also used. Suzano is raising funds to strengthen its capital structure. BTG Pactual and JPMorgan are global coordinators, with Banco do Brasil, Bradesco and Itau as bookrunners.

Posted inDaily Brief

Banvor to Get Equity Injection

Banco Votorantim is preparing a BRL2bn ($971m) equity increase, says Banco do Brasil, which owns half of the Brazilian lender. BRL1bn would come from Banco do Brasil and the other BRL1bn from Grupo Votorantim, through the Votorantim Financas unit. It does not offer additional details of the operation, which is subject to shareholder approval.

Posted inDaily Brief

Cencosud Pleased with NY Debut: Paulmann

The pricing of Cencosud’s $546m equity sale was in line with the company’s expectations, its top officials say, as the Chilean supermarket operator debuts its shares in New York and raises funds for expansion. “To have 6x demand for the offer is extraordinary, especially on a day when the US market fell 250 points” founder and chairman Horst Paulmann tells LatinFinance. “Leaving 6%-7% on the table wasn’t a mistake – quite the contrary. It was in line with our philosophy of live and share,” he adds, noting that as in the retail business, the most important thing isn’t always the lowest price, but rather price with quality. The retailer sold 45.5m shares in Santiago at CLP2,600 ($5.17) each, and 59.5m shares in the form of ADS at $15.61 each, including an overallotment option. The 2,600 price represents a 7% discount to the previous CLP2,795.9 closing price, and did not meet a CLP2,730.3 minimum the issuer had previously indicated. Total demand was CLP1.57trn, with CLP1.08trn in competitive demand. About 47% of the sale went to long-only ADR buyers, with 22% to domestic pensions, 8% to domestic retail, 7% to other local investors, 6% to non-ADR buying foreigners, and the remainder to other investors, the company says. Cencosud is raising funds to pay down debt and to fund the acquisition of Jumbo Retail Argentina, in addition to general corporate purposes. “This will give us the flexibility to grow in the next years. We are very comfortable with the capital increase,” CEO Daniel Rodriguez tells LatinFinance. With no large maturities in the next three years and last year’s $750m international bond under its belt, Rodriguez does not expect new fundraising of any kind in the near future, as the retailer turns its focus to organic expansion. “We see Brazil as a great market. Brazil in the last 4 years in the supermarkets segment has become our biggest operation, and we think in the next 3 years it will offer much opportunity. Our focus will be on organic growth in super

Posted inDaily Brief

Totvs Focused on Eventual NY Debut

In the midst of ongoing expansion and consolidation of its sector, Brazilian IT and software provider Totvs sees an eventual New York equity listing as a way to increase exposure and perhaps raise new funds. “We are working to be prepared to list in the US at the right moment. The reasoning is clear to be in New York – to be at the global standard and be listed along with comparable businesses,” CFO Alexandre Dinkelmann tells LatinFinance, noting especially a lack of peers in Brazil. The move would not be immediate, and Totvs is looking at a 3-year horizon for the listing, which could involve the raising of new funds. Mostly, however the company is not in need of new funds, thanks to a strong cash flow, even as they continue acquiring. “We are always looking at opportunities in Brazil and outside of Brazil, the deal flow will continue and we will be a natural consolidator,” Dinkelmann says. Brazil is the cornerstone, and LatAm beyond that, but he says the goal is to lead the market for SME services in the emerging markets.

Posted inDaily Brief

Brazil Pharma Prices FO

Brazil Pharma has priced a BRL553m ($268m) equity follow-on, landing at a 2.6% discount. The retail pharmaceutical company sold 52.8m primary shares, and 7.0m secondary shares at BRL9.25 each, including the exercise of a 15% greenshoe. This level compares to Thursday’s 9.50 closing price, which had lost 0.52% Thursday, in a session when the Bovespa plummeted nearly 3.0%. Half of the primary proceeds are going to strengthening the issuer’s capital structure, 40% to new acquisitions, and the remainder to making improvements to existing operations. The secondary portion featured shares sold by the Silveira family. BTG Pactual, Bradesco and Citi managed the sale.

Posted inDaily Brief

Cencosud Set to Price

Cencosud was set to emerge early this morning with the price for an approximately $500m equity follow-on. The Chilean retailer closed books Thursday afternoon on the sale of 91.3m shares in Chile and New York, and was heard still pricing that evening. The transaction would raise CLP255.2bn ($508m) at Thursday’s CLP2,795.9 closing price, though investors were expecting at least some discount. Though most agree the stock is cheap relative to other large LatAm retailers, the company’s Argentine assets – proceeds from the sale go partially to paying for the acquisition of Jumbo Retail Argentina – were heard to have raised some concern. “For long-term investors this seems like an attractive entry point. It trades at a discount to names such as Exito and Walmex,” says a New York investor looking at the transaction, noting that Argentina raises some concern but is still a small part of the picture. “We consider Cencosud’s current trading level to be very attractive,” Veronica Perez, analyst at BCI, tells LatinFinance. The retailer trades at 17.8x 2012 earnings and 13.9x 2013 earnings, according to Deutsche Bank, meaning a 13% discount to emerging market peers. The bank highlights solid organic expansion, solid brands in compelling markets like Peru and Brazil, as well as defensive features. Following the sale, Cencosud is set to launch a rights offering period to sell up to an additional 138m shares and set aside 27m for employees, all part of a capital raise approved last year. The supermarket operator is raising funds to pay down debt and to fund the acquisition of Jumbo Retail Argentina, in addition to general corporate purposes. Each ADS in the New York portion is worth 3 common shares, and initially referenced by ADRs. Credit Suisse, JPMorgan, Morgan Stanley, UBS, Santander and BBVA are managing the deal.

Posted inDaily Brief

JBS Wraps Up Vigor Exchange

JBS has finalized the 1-for-1 swap of its shares for those of Vigor Alimentos, it says, getting 118m shares, less than the 149.7m it had targeted in the spinoff. The operation was worth about BRL939.3m ($456m), and done at BRL7.96 per share. Bradesco advised JBS in the process. JBS shares closed at BRL6.05 Thursday.

Posted inDaily Brief

Equity Follow-ons Set to Price

Chile’s Cencosud and Brazil’s Brazil Pharma are set to test equity investor appetite through follow-ons pricing today. Bankers, investors and analysts expect follow-ons and some of the larger IPOs to get done. Cencosud is offering 91.3m shares in the form of ADS, a sale that would raise CLP293.06bn ($586m) at Wednesday’s CLP2,791 closing price, assuming the use of a 15% greenshoe. Books are scheduled to close this afternoon, with the pricing available as soon as the evening. The Chilean retailer would then launch a rights offering period to sell up to an additional 138m shares, raising as much as an additional $771m. Though Andean stocks are often considered expensive at the moment, Cencosud is seen offering a low entry point to the LatAm retail sector. Its 17.8x 2012 P/E ratio means it trades at a 13% discount to EM peers, according to a Deutsche Bank report. The supermarket operator is raising funds to pay down debt and to fund the acquisition of Jumbo Retail Argentina, in addition to general corporate purposes. Each ADS would be worth 3 common shares, and initially referenced by ADRs. Credit Suisse, JPMorgan, Morgan Stanley, UBS, Santander and BBVA are managing the deal, done as part of a $2bn total capital increase approved last year. Brazil Pharma is also set to price a follow-on today. The retail pharmaceutical company plans to sell 45m primary shares, and 7m secondary shares owned by members of the Silveira family. This would indicate a BRL571m ($281m) sale, based on Wednesday’s BRL9.55 close, and assuming a 15% greenshoe. A 20% hot issue is also available. Half of the primary proceeds would go to strengthening the issuer’s capital structure, 40% to new acquisitions, and the remainder to making improvements to existing operations. BTG Pactual, Bradesco and Citi are managing.

Posted inDaily Brief

Itau Takes YPF Stake

Itau is the latest creditor to come away with a piece of Argentina’s YPF as a result of a loan default by the minority-holding Eskenazi family, YPF says. The 3.6% stake would be worth about ARP1.11bn ($247m) at Wednesday’s ARP78.5 closing price. The Eskenazi-owned Petersen Group had used high YPF dividends to meet obligations on the $1bn syndicated loan, but the government changed the dividend policy when it nationalized a 51% stake in April. “The acquirer doesn’t intend to obtain a greater holding or take control of the company,” YPF says, citing a letter from the Itau unit. Carlos Silm, through his Inbursa bank, recently came away with a 8.4% position, also through the default.

Posted inDaily Brief

Berry Exporter Begins IPO Roadshow

Chile’s Hortifrut is scheduled to begin meeting investors today to market an IPO that could raise around $75m, according to bankers familiar with the process. The exact date of the pricing remains to be determined, with investor meetings likely to last 2-3 weeks. The exporter of berries is selling up to 103.6m primary shares, representing about 29% of the company post-float, in a sale said to target mostly domestic investors. Hortifrut is raising funds for investment in new facilities and export capacity, with an eye on opening new markets in Asia and LatAm. Chilean brokerages Celfin and Penta are managing the sale. Controlled by the Moller family, Hortifrut has growing and distribution operations including LatAm, North America and Europe and is among the world’s largest exporters of blueberries, raspberries, strawberries and blackberries. It posted $22.7m in Ebitda in 2011, up from $13.5m in 2012. While bankers admit the current state of the global markets is challenging for all equity deals, smaller IPOs not depending on international buyers may stand a better chance of completion than larger IPOs. Thursday should see follow-on sales from fellow Chilean Cencosud and from Brazil Pharma, with a number of transactions possibly to follow in the next 4-5 weeks.

Gift this article